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Improving Antivenom to Save Lives and Limbs
Antivenom for snakebites is produced by immunization of large mammals with snake venom using a 
traditional and expensive method developed in the 1890’s. Due to the animal origin, the products are 
highly immunogenic and come with a high risk of adverse side effects such as serum sickness and 
anaphylaxis, possibly leading to death  [1].
This project aims at replacing existing snake antivenoms with a mixture of recombinant, 
humanized antibodies produced by modern cell-based fermentation technology [2]. It is anticipated 
that such an antivenom will reduce the current high risk of severe side effects, reduce cost, and thereby 
can be sold at 1/10 of the current price making the essential medicine available for > 700 M Africans 
[3].
Modern day technology allows development of monoclonal antibodies (mAbs) targeting snake 
toxins, however, identification, characterization of immunogenic features (B-cell epitopes), and 
availability of purified snake toxins or non-toxic analogs currently constitute major bottlenecks blocking 
the development of recombinant mAbs. We have set out to remove these bottlenecks starting by 
mapping antibody binding sites of existing horse-derived products and purified antibodies from 
snakebite victims using high-density peptide microarrays. Moreover, we are developing homology 
models of all relevant mamba toxins to map conserved sites and identify key residues for toxicity. 
Figure 2 – Schematic overview of research approach.
Figure 1 – The Sub-Saharan antivenom crisis. Overview of the vicious cycle fueled by the current 
production method of antivenom and dangerously inappropriate products of Indian origin marketed by 
unscrupulous manufacturers dominating the unregulated African market [4]. WHO describes 
snakebites as one of the Worlds most neglected tropical diseases and the antivenom situation in Sub-
Saharan Africa as a long-standing crisis [5]. 
Figure 3 – Homology model of clinically relevant toxin from mamba (Dendroaspis) snakes. Surface and 
cartoon representations of short neurotoxin 1 (SN1) illustrating interspecies variation and the idea of 
finding one cross-reactive mAb. SN1 is a member of the large and diverse family of three-fingered 
toxins (3FTx). SN1 is known to antagonize the neuromuscular nicotinic acetylcholine receptor (nAChR) 
using finger 1 and 2 for binding [6]. Templates for homology model: 3ERA (crystal structure of mutant 
related Erabutoxin a from a sea snake with low affinity for nAChR) [7] and 2QC1 (nAChR bound 
distantly related α-bungarotoxin from the many-banded krait) [8].
Modeling Short Neurotoxin 1 from Mamba Snakes 
Figure 4 – Identification of residues important for toxicity using homology modeling. Left: Key 
interactions between nAChR and finger 2 of the co-crystalized α-bungarotoxin (orange). R36 
highlighted (yellow). Right: Homology model of mamba SN1 aligned to nAChR reveals an arginine 
residue, R31 (yellow), at a similar position in binding pocket. Below: Alignment of the three mamba 
SN1s and α-bungarotoxin.
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Figure 5 – Schematic overview of upcoming challenges related to protein research.
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